Zhejiang Jolly Pharmaceutical Co., Ltd. announced on August 12 that its marketed product Linglianhua Granules has received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, agreeing to conduct clinical trial research for a new functional indication. The proposed new indication is perimenopausal syndrome with anxiety state of heart-kidney disharmony pattern. The product's registration classification is Category 2.3 of traditional Chinese medicine, with acceptance number CXZL2600050. Linglianhua Granules is one of the company's Wuling series products and is an exclusive over-the-counter product in China. It uses Wuling fungal powder as the core raw material, combined with Chinese medicinal materials such as glossy privet fruit, thinleaf milkwort root, and yerbadetajo herb. It was originally used for perimenopausal syndrome of heart-kidney disharmony pattern. The company stated that after this approval, it will organize and carry out clinical trials. Due to the long cycle, multiple stages, and high risks of drug research and development, this matter will not have a significant impact on performance, and there is uncertainty in subsequent clinical trials and market launch.
Zhejiang Jolly Pharmaceutical Co LtdClinical trial approval for new indication of Linglianhua Granules
